Payment overview · 2025
General Payments
$556.92
34 reported records · 14 companies
Healthcare provider profile · identity verified
Joseph Michael Mowery, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SIOUX FALLS, SD · NPI 1386919579
Verified facts
What the public records show
CMS Open Payments records show Joseph Michael Mowery, D.O. received $556.92 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.66 | 34.6% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.75 | 12.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.62 | 9.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.33 | 7.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.65 | 5.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.60 | 5.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.57 | 4.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.53 | 3.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.25 | 3.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.29 | 3.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.48 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.48 | 2.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.84 | 2.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.87 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $556.92 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $130.23 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.60 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.75 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.75 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.43 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.62 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.60 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.60 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $28.60 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.25 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 253 | 60 |
| Lisinopril | Lisinopril | 178 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 39 |
| Simvastatin | Simvastatin | 127 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 28 |
| Omeprazole | Omeprazole | 106 | 28 |
| Gabapentin | Gabapentin | 104 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 96 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 27 |
| Tramadol Hcl | Tramadol Hcl | 90 | 17 |
| Trazodone Hcl | Trazodone Hcl | 78 | 21 |
| Prednisone | Prednisone | 75 | 60 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Losartan Potassium | Losartan Potassium | 74 | 21 |
| Lorazepam | Lorazepam | 72 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 18 |
| Metformin Hcl | Metformin Hcl | 67 | 14 |
| Famotidine | Famotidine | 64 | suppressed |
| Allopurinol | Allopurinol | 63 | 15 |
| Metformin Hcl Er | Metformin Hcl | 62 | 16 |
| Meloxicam | Meloxicam | 60 | 14 |
| Eliquis | Apixaban | 58 | suppressed |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 16 |
| Ondansetron Odt | Ondansetron | 49 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | 11 |
| Furosemide | Furosemide | 42 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 18 |
| Cephalexin | Cephalexin | 20 | 16 |
| Digoxin | Digoxin | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Glipizide | Glipizide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | 11 |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Imiquimod | Imiquimod | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $556.92 · 34 records | ABBVIE INC. | CAPVAXIVE, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, FARXIGA, GARDASIL 9, INSPIRE, LEQVIO, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, ROTATEQ, TRINTELLIX, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error